AstraZeneca’s £93m headache as it dumps another new drug
Struggling AstraZeneca today faced yet another blow when it had to dump a new arthritis treatment because clinical trials showed patients were hit with side-effects including the common cold.
Pulling development on fostamatinib, a rheumatoid arthritis pill, means a $140 million (£93 million) impairment charge. But analysts were more worried about Astra’s floundering pipeline. The experimental medicine was one of the very few late-stage drugs in Astra’s research labs, and Britain’s second-biggest drugmaker had put it through clinical trials for two and a half years, on more than 2100 patients.
Fostamatinib, which Astra was working on with US biotech Rigel Pharmaceuticals, was seen as a potential competitor to drugs such as Abbott Laboratories’ Humira, the world’s best-selling prescription medicine, in an arthritis market worth $20 billion (£13 billion).
But Astra admitted patients taking part in the drug’s trials had faced a cocktail of side-effects including hypertension, diarrhoea, nausea, headache and colds. Analysts said that meant more than six drug failures from Astra’s pipeline in recent years. A string of AstraZeneca’s big-selling drugs fell out of patent last year, leaving revenues down 17%. The US patents for its best-selling drugs, Nexium ulcer pills and cholesterol-buster Crestor, expire within three years.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies